Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
The U.S. IPO market has seen an uptick amid falling interest rates, strong equity markets, and hopes of a friendlier ...
1cBio and Alesta Therapeutics Announce Exclusive Global Licensing Agreement for a Novel Potentially First-in-Class Small Molecule for Hypophosphatasia
Bio, Inc. ("1cBio") an emerging biotech company developing precision medicines for significant unmet needs, and Alesta Pharmaceuticals ("Alesta") a leader in developing first-in-class small molecules ...
Vertex turns to Watertown biotech for gene-editing medicines pact
Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...
BioPharma Dive23h
Vertex, startup Orna to partner on gene editing research
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis ...
today.ucsd52m
Uncovering Clues to a Natural Gene-Editing Technique
This research deepens our understanding of the evolutionary origin of DGRs and may be applicable to future gene-editing techniques. The study was published January 8, 2025 in Nature and was led by ...